Antidiabetic medications and weight loss
Pro Research Analysisby 
Searched over 200M research papers
Antidiabetic Medications and Weight Loss: Key Drug Classes and Effects
GLP-1 Receptor Agonists and Weight Loss
Glucagon-like peptide-1 (GLP-1) receptor agonists, such as liraglutide, semaglutide, and exenatide, are among the most effective antidiabetic medications for promoting weight loss in people with type 2 diabetes. Clinical studies and real-world data consistently show that these drugs can lead to significant reductions in body weight, with semaglutide and liraglutide often resulting in weight loss greater than 5% of initial body weight, while exenatide tends to produce a milder effect Lazzaroni2021Haddad2023Singh2021. These medications are also FDA-approved for obesity management, further supporting their role in weight reduction for patients with or without diabetes Haddad2023Singh2021. Newer combinations, such as CagriSema (cagrilintide plus semaglutide), are being investigated for even greater efficacy in lowering both blood sugar and body weight .
SGLT2 Inhibitors and Moderate Weight Loss
Sodium-glucose cotransporter-2 (SGLT2) inhibitors, including empagliflozin, canagliflozin, ertugliflozin, and dapagliflozin, are associated with moderate weight loss, typically between 3.2% and 5% of initial body weight Lazzaroni2021Haddad2023Popovic2023. These agents are effective in both type 2 and, as adjuncts to insulin, type 1 diabetes, though their use in type 1 diabetes is limited by the risk of diabetic ketoacidosis . SGLT2 inhibitors also offer additional benefits, such as improved cardiovascular and renal outcomes .
Metformin and Mild Weight Loss
Metformin, a first-line oral antidiabetic medication, is well-known for its mild weight loss effects or weight neutrality Lazzaroni2021Haddad2023Shurrab2020+1 MORE. While it is not approved specifically for weight management, metformin is often preferred in overweight or obese patients with type 2 diabetes due to its favorable impact on body weight compared to other antidiabetic drugs Shurrab2020Higbea2017. However, long-term safety for off-label use in weight loss remains uncertain, and potential adverse effects should be considered .
DPP-4 Inhibitors and Weight Neutrality
Dipeptidyl peptidase-4 (DPP-4) inhibitors generally have a neutral or very mild effect on weight, making them a suitable option for patients where weight gain is a concern but significant weight loss is not expected Haddad2023Higbea2017.
Medications Associated with Weight Gain
Some antidiabetic medications, such as insulin, sulfonylureas, thiazolidinediones, and meglitinides, are linked to weight gain Patange2023Higbea2017Levin2022. This can be a challenge for patients aiming to lose weight, and the use of these agents should be carefully balanced with the benefits of glycemic control Higbea2017Levin2022. Despite this, lifestyle interventions and digital therapeutics programs can still help patients achieve weight loss even when using these medications .
Real-World Effectiveness and Clinical Practice Trends
Real-world data confirm that patients using antidiabetic medications associated with weight loss, such as SGLT2 inhibitors and metformin, experience greater reductions in weight and waist circumference compared to those on weight-gaining medications . However, the use of anti-obesity medications among patients with type 2 diabetes remains low, and many patients are still prescribed weight-inducing antihyperglycemic agents, potentially compromising weight loss goals .
Conclusion
Antidiabetic medications vary widely in their effects on body weight. GLP-1 receptor agonists and SGLT2 inhibitors are the most effective for weight loss, with metformin offering mild benefits and DPP-4 inhibitors being weight neutral. Insulin and certain oral agents can cause weight gain, highlighting the importance of individualized therapy. Despite the availability of effective weight-loss medications, their use in clinical practice is still limited, suggesting a need for stronger guideline implementation and patient education to optimize both glycemic control and weight management in diabetes care Lazzaroni2021Haddad2023Patange2023+6 MORE.
Sources and full results
Most relevant research papers on this topic